

Supporting Information
for
**Extending the utility of [Pd(NHC)(cinnamyl)Cl]
precatalysts: Direct arylation of heterocycles**

Anthony R. Martin, Anthony Chartoire, Alexandra M. Z. Slawin and Steven P. Nolan*

Address: EastCHEM School of Chemistry, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK

Email: Steven P. Nolan* - snolan@st-andrews.ac.uk

* Corresponding author

**Synthesis and characterization of complex 4; compound
characterization data for all the direct arylated products and copies
of their ^1H and ^{13}C NMR spectra**

Table of contents

General considerations	S2
Synthesis and characterisation of 4	S3–6
Optimisation reactions	S7–8
General procedure for the direct arylation of heterocycles	S9
Characterisation data of compounds 8a–g, 10a–c, 12a–c and 14a–c	S9–16
References	S16
^1H and ^{13}C NMR spectra of all compounds	S17–36

General considerations:

All aryl halides and heterocycles were used as received. Anhydrous solvents (1,4-dioxane, tetrahydrofuran (THF), dimethylacetamide (DMA), dimethylformamide (DMF) and toluene) and the bases (NaOt-Bu, KOt-Bu, Na₂CO₃, K₂CO₃, Cs₂CO₃, KOH, LiHMDS) were stored in a glovebox and used as received. [{Pd(cinnamyl)(μ-Cl)}₂] is commercially available (UMICORE) and was stored in a glovebox.

Flash chromatography was performed on silica gel 60 Å pore diameter and 40–63 μm particle size.


¹H and ¹³C Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker-300 MHz or 400 MHz spectrometer at ambient temperature in CD₂Cl₂ or CDCl₃. Chemical shifts (δ) are reported in ppm, relative to the solvent residual peak CD₂Cl₂ (5.32 ppm and 54.00 ppm) and CDCl₃ (7.26 ppm and 77.16 ppm). Data for ¹H NMR are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, br = broad signal, m = multiplet), coupling constants (J) in hertz and integration.

Elemental analyses were performed at London Metropolitan University 166–220 Holloway Road, London, N7 8DB.

Gas chromatography analyses (GC) were performed on an Agilent 7890A apparatus equipped with a flame ionization detector and a (5%-phenyl)methylpolysiloxane column (30 m, 320 μm, film: 0.25 μm). Flow rate 1 mL/min constant flow, inlet temperature 260 °C, column temperature 50 °C, 20 °C/min increase to 300 °C (held for 1 min), total time 7.6 min.

Mass spectrometry was performed by the EPSRC National Mass Spectrometry Service Centre at Swansea University, Grove building, Singleton Park, Swansea, SA2 8PP, Wales, UK

Synthesis of [Pd(IPr^{*Tol})(cin)Cl] 4:



Synthesis of the 2,6-bis(di-*p*-tolylmethyl)-4-methylaniline (**B**):

In a 250 mL round-bottomed flask, *p*-toluidine (3.34 g, 32 mmol) and di-*p*-tolylmethanol (**A**) [1] (13.58g, 64 mmol) were stirred together at 160°C until liquid. A solution of zinc chloride (2.18 g, 16 mmol) in HCl 36% (2.7 mL) was added dropwise to the reaction mixture. The flask was then opened to allow water evaporation, and stirring was continued at 160°C until solidification of the reacting media (1.5 h). The residue was then allowed to cool to room temperature, dissolved in CH_2Cl_2 (300 mL), and washed with NH_4Cl aq. saturated solution and brine. The organic layer was subsequently dried over K_2CO_3 , and 20 g of silica gel was added to it. After filtration and concentration in *vacuo*, the 2,6-bis(di-*p*-tolylmethyl)-4-methylaniline (**B**) was obtained as an off-white powder (14.77 g, 93%), which did not need further purification.

^1H NMR (CDCl_3 , 400 MHz) δ 2.09 (s, 3H, $\text{CH}_3\text{-Tol}$), 2.37 (s, 12H, $\text{CH}_3\text{-Tol}$), 3.37 (br, 2H, NH_2), 5.43 (s, 2H, CH), 6.46 (s, 2H, H_{Ar}), 7.04 (d, J 8.2 Hz, 8H, H_{Ar}), 7.13 (d, J 7.9 Hz, 8H, H_{Ar}).

^{13}C NMR (CDCl_3 , 75 MHz) δ 21.2 (CH_3), 21.3 (CH_3), 51.8 (CH), 126.6 (C_{Ar}), 129.0 (CH_{Ar}), 129.3 (CH_{Ar}), 129.5 (CH_{Ar}), 129.6 (C_{Ar}), 136.1 (C_{Ar}), 139.8 (C_{Ar}) 140.2 (C_{Ar}).

HRMS (NESI) $^+$: Calcd for $\text{C}_{37}\text{H}_{38}\text{N}$: 495.2999, found: 495.2994.

Synthesis of the *N,N'*-bis(2,6-bis(di-*p*-tolylmethyl)-4-methylphenyl)diazabutadiene (**C**):

To a solution of aniline **B** (14.45 g, 29.15 mmol) dissolved in 300 mL of CH_2Cl_2 , was added MgSO_4 (15 g), glyoxal (40 wt % in H_2O , 3.32 mL, 29.12 mmol) and a catalytic amount of formic acid (5 drops). The reacting mixture was stirred at room temperature for 2 days prior to filtration. The cake was washed profusely with CH_2Cl_2 until the filtrate became colourless. The latter was then concentrated to dryness and the residue was suspended in ethyl acetate. The slurry was finally filtered and washed with ethyl acetate (2 $\times$ 50 mL) to afford **C** as a bright yellow powder (12.88 g, 87%), which was dried under high vacuum.

^1H NMR (CD_2Cl_2 , 400 MHz) δ 2.12 (s, 6H, $\text{CH}_{3-\text{Tol}}$), 2.27 (s, 24H, $\text{CH}_{3-\text{Tol}}$), 5.15 (s, 4H, CH), 6.68 (s, 4H, H_{Ar}), 6.85 (d, J 7.9 Hz, 16H, H_{Ar}), 7.02 (d, J 8.1 Hz, 16H, H_{Ar}), 7.28 (s, 2H, H_{imine}).

^{13}C NMR (CD_2Cl_2 , 75 MHz) δ 21.3 (CH_3), 21.6 (CH_3), 50.9 (CH), 129.3 (C_{Ar}), 129.5 (CH_{Ar}), 129.8 (CH_{Ar}), 132.8 (C_{Ar}), 134.0 (C_{Ar}), 136.4 (CH_{Ar}), 141.5 (CH_{Ar}) 147.3 (C_{Ar}), 164.4 ($\text{C}=\text{N}$).

HRMS (NESI) $^+$: Calcd for $\text{C}_{76}\text{H}_{73}\text{N}_2$: 1013.5768, found: 1013.5767.

Synthesis of the 1,3-bis(2,6-bis(di-*p*-tolylmethyl)-4-methylphenyl)imidazolium chloride, $\text{IPr}^{\text{Tol}}\cdot\text{HCl}$ (**5**):

Diazabutadiene **C** (7.34 g, 7.24 mmol) dissolved in chloroform (50 mL) at 60 $^\circ\text{C}$ was treated with paraformaldehyde (261 mg, 8.69 mmol) and zinc chloride (1.185 g,

8.69 mmol) as a solution in HCl 36% (1.5 mL), for 1.5 h. The reaction mixture was then diluted with CH₂Cl₂ (50 mL), and washed with HCl 2 M (50 mL) and brine. The organic layer was subsequently dried over MgSO₄, filtered and concentrated to dryness. The resulting residue was finally suspended in Et₂O, filtered and washed thoroughly with Et₂O (3 × 15 mL) to afford **5** as a colourless powder (4.96 g, 65%)

¹H NMR (CDCl₃, 300 MHz) δ 2.18 (s, 6H, CH₃-Tol), 2.28 (s, 24H, CH₃-Tol), 5.16 (s, 4H, CH), 5.64 (s, 2H, H_{imid}), 6.65 (d, *J* 7.8 Hz, 8H, H_{Ar}), 6.76 (s, 4H, H_{Ar}), 6.90 (d, *J* 7.7 Hz, 8H, H_{Ar}), 7.05 (s, 16H, H_{Ar}), 12.68 (br, 1H, H_{imid}).

¹³C NMR (CDCl₃, 75 MHz) δ 21.2 (CH₃), 22.0 (CH₃), 50.7 (CH), 123.7 (CH_{imid}), 129.2 (CH_{Ar}), 129.3 (CH_{Ar}), 129.4 (CH_{Ar}), 130.0 (CH_{Ar}), 130.7 (CH_{Ar}), 136.2 (C_{Ar}), 136.4 (C_{Ar}), 139.4 (C_{Ar}), 139.6 (C_{Ar}), 140.9 (C_{Ar}), 141.3 (C_{Ar}).

HRMS (NESI)⁺: Calcd for C₇₇H₇₃N₂ 1025.5768, found: 1025.5748.

Synthesis of the [Pd(IPr^{*Tol})(cinnamyl)Cl] (**4**):

In a glovebox, a 500 mL round-bottomed flask equipped with a magnetic stirring bar was charged with IPr^{*Tol}•HCl (**5**) (2.00 g, 1.88 mmol) and 150 mL of THF. KO^{*t*}-Bu (230 mg, 2.05 mmol) was then added as a powder and the reacting media was stirred at room temperature for 4 h. [{Pd(cinnamyl)(μ-Cl)}₂] (443 mg, 0.85 mmol) was subsequently added, as a solution in THF, and stirring was continued overnight outside of the glovebox. The solvent was eventually evaporated off, and the crude residue was dissolved into CH₂Cl₂ (15 mL) before being passed through a bed of Celite[®] over silica (2 cm of each). The collected filtrate was concentrated to dryness and further dried under high vacuum. Complex **5** was finally recovered as a pale yellow powder (2.11 g, 97%).

¹H NMR (CD₂Cl₂, 400 MHz) δ 1.15 (d, *J* 12.0 Hz, 1H, H_{cin}) 2.25–2.32 (m, 30H, CH₃), 2.54 (d, *J* 6.5 Hz, 1H, H_{cin}), 4.48 (d, *J* 12.6 Hz, 1H, H_{cin}), 4.92–4.96 (m, 1H, H_{cin}), 5.41 (s, 2H, H_{imid}), 5.70 (s, 2H, CH), 5.86 (s, 2H, CH), 6.69–6.73 (m, 8H, H_{Ar}), 6.90–6.94 (m, 12H, H_{Ar}), 7.03–7.09 (m, 8H, H_{Ar}), 7.15–7.21 (m, 8H, H_{Ar}), 7.36–7.46 (m, 5H, H_{Ar}).


¹³C NMR (CD₂Cl₂, 75 MHz) δ 21.2 (CH₃), 21.3 (CH₃), 22.0 (CH₃), 47.8 (CH₂-Cin), 51.2 (CH), 91.0 (CH_{Cin}), 109.4 (CH_{Cin}), 123.9 (CH_{imid}), 127.5 (CH_{Ar}), 128.0 (CH_{Ar}), 128.9 (CH_{Ar}), 129.2 (CH_{Ar}), 129.5 (CH_{Ar}), 130.3 (CH_{Ar}), 130.9 (CH_{Ar}), 136.3 (C_{Ar}), 138.6 (C_{Ar}), 138.7 (C_{Ar}), 141.4 (C_{Ar}), 141.5 (C_{Ar}), 141.6 (C_{Ar}), 142.0 (C_{Ar}), 142.4 (C_{Ar}), 142.5 (C_{Ar}), 183.1 (C_{Ar}).

Elemental Analysis: Calcd for C₈₆H₈₁N₂ClPd, C (80.42), H (6.36), N (2.18); found C (80.54), H (6.48), N (2.24).

X-Ray: CCDC 887349 (See Supporting Information Files 2 and 3).

Optimisation reactions:

Optimisation of the solvent/ base combination^a


		
Solvent	Base	Conversion (%) ^b
Dioxane	LiHMDS	74
Dioxane	Cs ₂ CO ₃	18
Dioxane	KOH	0
Dioxane	KOt-Bu	0
Dioxane	NaOt-Bu	77
Toluene	LiHMDS	31
Toluene	Cs ₂ CO ₃	0
Toluene	KOH	0
Toluene	KOt-Bu	9
Toluene	NaOt-Bu	34
DMF	LiHMDS	0
DMF	Cs ₂ CO ₃	>99
DMF	KOH	0
DMF	KOt-Bu	0
DMF	NaOt-Bu	11
DMF	KOAc	96
DMA	LiHMDS	8
DMA	KOH	27
DMA	KOt-Bu	48
DMA	NaOt-Bu	44
DMA	Cs ₂ CO ₃	>99
DMA	KOAc	91
DMA	Cs ₂ CO ₃	25 ^c
DMA	K ₂ CO ₃	>99 ^c
DMA	Na ₂ CO ₃	59 ^c

^aReaction conditions: benzothiophene (0.6 mmol), 4-bromotoluene (1.2 mmol), base (0.9 mmol), pivalic acid (30 mol %), [Pd(SIPr)(cin)Cl] (2 mol %), solvent (2 mL).

^bConversion to C–H arylated product determined by GC.

^c[Pd(SIPr)(cin)Cl] (1 mol %)

Optimisation of the catalyst loading^a


		
Catalyst loading	X	Conversion (%) ^b
2 mol %	Br	>99
1 mol %	Br	>99
0.5 mol %	Br	>99
0.1 mol %	Br	>99
0.1 mol %	Cl	0
0.1 mol %	I	45
0.05 mol %	Br	92
0.025 mol %	Br	80 (50) ^c
0.01 mol %	Br	35

^aReaction conditions: benzothiophene (0.6 mmol), 4-bromotoluene (0.6 mmol), K₂CO₃ (0.9 mmol), pivalic acid (30 mol %), [Pd(SIPr)(cin)Cl] (x mol %), DMA (2 mL).

^bConversion to C–H arylated product determined by GC.

^cYield in parenthesis refers to a reaction performed in DMF.

Additives screening^a

		
Additives	Additive loading	Conversion (%) ^b
CF ₃ COOH	30 mol %	<1
CH ₃ COOH	30 mol %	5
PhCOOH	30 mol %	12
PivOH	30 mol %	75
PivOH	20 mol %	66
PivOH	10 mol %	55

^aReaction conditions: benzothiophene (0.6 mmol), 4-bromotoluene (0.6 mmol), K₂CO₃ (0.9 mmol), additives (x mol %), [Pd(SIPr)(cin)Cl] (0.025 mol %), DMA (2 mL).

^bConversion to C–H arylated product determined by GC.

^cYield in parenthesis refers to a reaction performed in DMF.


General procedure for the direct arylation of heterocycles

In a glovebox, a vial containing a stirring bar was charged with K_2CO_3 (124 mg, 0.9 mmol, 1.5 equiv) and pivalic acid (0.18 mmol, 18 mg, 30 mol %), and sealed with a screw cap fitted with a septum. The heterocycle (0.6 mmol, 1.0 equiv) and/or the arylbromide (0.6 mmol, 1.0 equiv) were added at this point if in solid form, and DMA (1.9 mL) was poured into the vial. Outside of the glovebox, the heterocycle and/or the aryl bromide were added at this point if in liquid form. Finally, $[\text{Pd}(\text{SiPr})(\text{cin})\text{Cl}]$ (**1**) was added as a 0.06 M solution in DMA (0.6–6 μmol , 10–100 μL , 0.01–0.1 mol %), and the vial was heated to 140 °C for 16 h. The solution was then cooled to room temperature, diluted with 40 mL of ethyl acetate and washed with water (2 $\times$ 20 mL) and brine (20 mL). The organic layer was dried over MgSO_4 , filtered and concentrated in vacuo. The crude residue was finally purified by either trituration in pentane (if not soluble) or by silica gel column chromatography.

Characterisation data of compounds 8a–8g, 10a–10c, 12a–12c and 14a–14c:

2-(*p*-tolyl)benzo[*b*]thiophene (8a) [2]

The general procedure yielded, after trituration in pentane, 120 mg (89%) of the title compound as an off-white solid.




^1H NMR (CD_2Cl_2 , 300 MHz) δ 2.40 (s, 3H, CH_3), 7.25–7.39 (m, 4H, H_{Ar}), 7.54 (s, 1H, H_{Ar}), 7.62–7.65 (m, 2H, H_{Ar}), 7.76–7.86 (m, 2H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 100 MHz) δ 21.5, 119.4, 122.7, 124.0, 124.7, 125.1, 126.8, 130.2, 131.9, 139.1, 139.8, 141.4, 144.9.

2-(*m*-tolyl)benzo[*b*]thiophene (8b) [3]:

The general procedure yielded, after flash chromatography on silica gel (pentane), 108 mg (80%) of the title compound as a colourless solid.




¹H NMR (CD₂Cl₂, 400 MHz) δ 2.44 (s, 3H, CH₃), 7.21 (br d, *J* 7.5 Hz, 1H, H_{Ar}), 7.32–7.41 (m, 3H, H_{Ar}), 7.56 (br d, *J* 7.9 Hz, 1H, H_{Ar}), 7.80–7.82 (m, 1H, H_{Ar}), 7.85–7.88 (m, 1H, H_{Ar}).

¹³C NMR (CD₂Cl₂, 100 MHz) δ 21.7, 119.9, 122.8, 124.0, 124.1, 124.9, 125.1, 127.6, 129.4, 129.7, 134.6, 139.4, 139.9, 141.3, 144.9.

2-(*o*-tolyl)benzo[*b*]thiophene (8c) [4]:

The general procedure yielded, after trituration in pentane, 104 mg (77%) of the title compound as a colourless solid.




¹H NMR (CD₂Cl₂, 300 MHz) δ 2.49 (s, 3H, CH₃), 7.25–7.43 (m, 6H, H_{Ar}), 7.48–7.51 (m, 1H, H_{Ar}), 7.81–7.84 (m, 1H, H_{Ar}), 7.80–7.82 (m, 1H, H_{Ar}), 7.86–7.89 (m, 1H, H_{Ar}).

¹³C NMR (CD₂Cl₂, 100 MHz) δ 21.4, 122.5, 123.6, 124.0, 124.7, 124.9, 126.5, 128.9, 131.1, 131.4, 134.6, 137.0, 140.6, 140.8, 144.0.

2-(4-methoxyphenyl)benzo[*b*]thiophene (8d) [2]:


The general procedure yielded, after trituration in pentane, 101 mg (70%) of the title compound as a colourless solid.



¹H NMR (CD₂Cl₂, 400 MHz) δ 3.85 (s, 3H, CH₃), 6.96–6.98 (m, 2H, H_{Ar}), 7.29 (ddd, *J* 7.8, 7.1 and 1.4 Hz, 1H, H_{Ar}), 7.34 (ddd, *J* 7.8, 7.1 and 1.3 Hz, 1H, H_{Ar}), 7.46 (d, *J* 0.8 Hz, 1H, H_{Ar}), 7.64–7.68 (m, 2H, H_{Ar}), 7.75–7.77 (m, 1H, H_{Ar}), 7.81–7.83 (m, 1H, H_{Ar}).
¹³C NMR (CD₂Cl₂, 100 MHz) δ 55.9, 114.9, 118.7, 122.7, 123.8, 124.5, 125.1, 127.4, 128.2, 139.6, 141.5, 144.6, 160.5.

2-(4-chlorophenyl)benzo[*b*]thiophene (8e) [2]:


The general procedure yielded, after trituration in pentane, 72 mg (49%) of the title compound as an off-white solid.



¹H NMR (CD₂Cl₂, 300 MHz) δ 7.33–7.38 (m, 2H, H_{Ar}), 7.39–7.44 (m, 2H, H_{Ar}), 7.57 (s, 1H, H_{Ar}), 7.66–7.69 (m, 2H, H_{Ar}), 7.78–7.81 (m, 1H, H_{Ar}), 7.83–7.86 (m, 1H, H_{Ar}).
¹³C NMR (CD₂Cl₂, 75 MHz) δ 120.5, 122.8, 124.2, 125.2, 125.3, 128.2, 129.6, 133.4, 134.5, 140.0, 141.2, 143.2.

2-(4-fluorophenyl)benzo[*b*]thiophene (8f) [2]:


The general procedure yielded, after trituration in pentane, 73 mg (53%) of the title compound as an off-white solid.



¹H NMR (CD₂Cl₂, 300 MHz) δ 7.12–7.18 (m, 2H, H_{Ar}), 7.30–7.40 (m, 2H, H_{Ar}), 7.52 (s, 1H, H_{Ar}), 7.69–7.74 (m, 2H, H_{Ar}), 7.78–7.86 (m, 2H, H_{Ar}).
¹³C NMR (CD₂Cl₂, 75 MHz) δ 116.5 (d, *J*_{CF} 22 Hz), 120.4, 122.7, 124.1, 125.0, 125.2, 128.7 (d, *J*_{CF} 8 Hz), 131.1 (d, *J*_{CF} 3 Hz), 139.9, 141.3, 143.5, 163.4 (d, *J*_{CF} 248 Hz).

4-(benzo[*b*]thiophen-2-yl)benzaldehyde (8g) [5]:

The general procedure yielded, after flash chromatography on silica gel (pentane), 53 mg (37%) of the title compound as a colourless solid.




¹H NMR (CD₂Cl₂, 300 MHz) δ 7.34–7.42 (m, 2H, H_{Ar}), 7.70 (s, 1H, H_{Ar}), 7.80–7.91 (m, 6H, H_{Ar}), 10.00 (s, 1H, CHO).

¹³C NMR (CD₂Cl₂, 75 MHz) δ 122.2, 122.9, 124.6, 125.4, 125.7, 127.1, 130.7, 136.3, 140.2, 140.7, 141.0, 142.9, 191.8.

HRMS (APCI)⁺: Calcd for C₁₅H₁₁OS 239.0525, found 239.0527.

2-(*p*-tolyl)-3-methylbenzo[*b*]thiophene (10a) [6]:

The general procedure yielded, after trituration in pentane, 121 mg (85%) of the title compound as an off-white solid.




¹H NMR (CD₂Cl₂, 300 MHz) δ 2.42 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 7.28–7.47 (m, 6H, H_{Ar}), 7.74 (dt, J 8.4 and 1.0 Hz, 1H, H_{Ar}), 7.82–7.85 (m, 1H, H_{Ar}).

¹³C NMR (CD₂Cl₂, 75 MHz) δ 13.0, 22.5, 122.5, 122.6, 124.6, 124.7, 127.7, 129.8, 130.0, 132.2, 138.5, 138.6, 139.2, 141.9.

2-(*o*-tolyl)-3-methylbenzo[*b*]thiophene (10b):

The general procedure yielded, after flash chromatography on silica gel, 119 mg (83%) of the title compound as a colourless solid.




^1H NMR (CD_2Cl_2 , 300 MHz) δ 2.21 (s, 3H, CH_3), 2.25 (s, 3H, CH_3), 7.24–7.30 (m, 1H, H_{Ar}), 7.32–7.37 (m, 4H, H_{Ar}), 7.44 (ddd, J 7.9, 7.1 and 1.3 Hz, 1H, H_{Ar}), 7.75 (ddd, J 7.9, 1.4 and 0.8 Hz, 1H, H_{Ar}), 7.85 (ddd, J 7.8, 1.4 and 0.7 Hz, 1H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 75 MHz) δ 13.0, 21.5, 122.5, 122.6, 124.6, 124.7, 127.7, 129.8, 130.0, 132.2, 138.5, 138.6, 139.2, 141.9.

HRMS (APCI) $^+$: Calcd for $\text{C}_{16}\text{H}_{15}\text{S}$ 239.0889, found 239.0891.

2-(4-fluorophenyl)-3-methylbenzo[*b*]thiophene (10c):

The general procedure yielded, after trituration in pentane, 76 mg (52%) of the title compound as an off-white solid.




^1H NMR (CD_2Cl_2 , 300 MHz) δ 2.46 (s, 3H, CH_3), 7.16–7.22 (m, 2H, H_{Ar}), 7.38–7.45 (m, 2H, H_{Ar}), 7.53–7.57 (m, 2H, H_{Ar}), 7.74–7.78 (m, 1H, H_{Ar}), 7.84–7.87 (m, 1H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 75 MHz) δ 12.9, 116.0 (d, J_{CF} 22 Hz), 122.6, 122.7, 125.0, 128.3, 131.4 (d, J_{CF} 3 Hz), 132.0 (d, J_{CF} 8 Hz), 137.3, 139.3, 141.7, 163.0 (d, J_{CF} 247 Hz).

HRMS (APCI) $^+$: Calcd for $\text{C}_{15}\text{H}_{11}\text{SF}$ 242.0560, found 242.0564.

2-(*p*-tolyl)-5-methylthiophene (12a) [7]:

The general procedure yielded, after flash chromatography on silica gel (pentane), 102 mg (90%) of the title compound as a colourless solid.




^1H NMR (CD_2Cl_2 , 300MHz) δ 2.35 (s, 3H, CH_3), 2.50 (s, 3H, CH_3), 6.73 (dq, J 3.4 and 1.1 Hz, 1H, H_{Ar}), 7.08 (d, J 3.5 Hz, 1H, H_{Ar}), 7.16–7.19 (m, 2H, H_{Ar}), 7.43–7.46 (m, 2H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 75MHz) δ 15.7, 21.4, 122.9, 125.7, 126.7, 130.0, 132.4, 137.5, 139.6, 142.5.

2-(4-methoxyphenyl)-5-methylthiophene (**12b**) [8]:

The general procedure yielded, after flash chromatography on silica gel (pentane), 92 mg (75%) of the title compound as a colourless solid.




^1H NMR (CD_2Cl_2 , 400 MHz) δ 2.48 (d, J 1.1 Hz, 3H, CH_3), 3.81 (s, 3H, CH_3), 6.71 (dq, J 3.5 and 1.2 Hz, 1H, H_{Ar}), 6.87–6.91 (m, 2H, H_{Ar}), 7.00 (d, J 3.5 Hz, 1H, H_{Ar}), 7.46–7.49 (m, 2H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 75 MHz) δ 15.7, 55.8, 114.7, 122.3, 126.7, 127.1, 128.0, 139.1, 142.3, 159.5.

2-(4-fluorophenyl)-5-methylthiophene (**12c**) [9]:

The general procedure yielded, after flash chromatography on silica gel (pentane), 66 mg (57%) of the title compound as a colourless solid.




^1H NMR (CD_2Cl_2 , 400 MHz) δ 2.51 (s, 3H, CH_3), 6.75 (dq, J 3.5 and 1.1 Hz, 1H, H_{Ar}), 7.05–7.11 (m, 3H, H_{Ar}), 7.54 (ddt, J 7.1, 5.2 and 2.5 Hz, 2H, H_{Ar}).

^{13}C NMR (CD_2Cl_2 , 75 MHz) δ 15.7, 116.2 (d, J_{CF} 22 Hz), 123.5, 126.8, 127.6 (d, J_{CF} 8 Hz), 131.6 (d, J_{CF} 3 Hz), 140.3, 141.2, 162.6 (d, J_{CF} 246 Hz).

3-(*p*-tolyl)imidazo[1,2-*a*]pyridine (**14a**) [10]:

The general procedure yielded, after flash chromatography on silica gel (DCM-MeOH: 0–2%), 92 mg or 86 mg (74% or 69%) of the title compound as a colourless solid.




¹H NMR (CD₂Cl₂, 300 MHz) δ 2.43 (s, 3H, CH₃), 6.86 (tt, *J* 6.9 and 1.3 Hz, 1H, H_{Ar}), 7.18 (ddt, *J* 9.1, 6.6 and 1.3 Hz, 1H, H_{Ar}), 7.34 (d, *J* 8.0 Hz, 2H, H_{Ar}), 7.47 (d, *J* 8.2 Hz, 2H, H_{Ar}), 7.60–7.63 (m, 2H, H_{Ar}), 8.34 (dt, *J* 7.0 and 1.3 Hz, 1H, H_{Ar}).

¹³C NMR (CD₂Cl₂, 75 MHz) δ 21.6, 112.8, 118.5, 124.0, 124.4, 126.3, 127.0, 128.3, 130.4, 132.7, 138.7, 146.5.

3-(4-methoxyphenyl)imidazo[1,2-*a*]pyridine (**14b**) [11]:

The general procedure yielded, after flash chromatography on silica gel (DCM-MeOH: 0–4%), 71 mg (53%) of the title compound as a colourless solid.




¹H NMR (CD₂Cl₂, 300 MHz) δ 3.85 (s, 3H, CH₃), 6.76 (td, *J* 6.8 and 1.3 Hz, 1H, H_{Ar}), 6.99–7.08 (m, 2H, H_{Ar}), 7.15 (ddd, *J* 9.1, 6.7 and 1.3 Hz, 1H, H_{Ar}), 7.39–7.51 (m, 2H, H_{Ar}), 7.57–7.63 (m, 2H, H_{Ar}), 8.26 (dt, *J* 7.0 and 1.2 Hz, 1H, H_{Ar}).

¹³C NMR (CD₂Cl₂, 75 MHz) δ 21.6, 112.8, 118.5, 124.0, 124.4, 126.3, 127.0, 128.3, 130.4, 132.7, 138.7, 146.5.

3-(4-fluorophenyl)imidazo[1,2-a]pyridine (14c) [11] (76%):

The general procedure yielded, after flash chromatography on silica gel (DCM-MeOH: 0–2%), 97 mg (76%) of the title compound as a colourless solid.





¹H NMR (CD₂Cl₂, 300 MHz) δ 3.85 (s, 3H, CH₃), 6.82 (td, *J* 6.8 and 1.2 Hz, 1H, H_{Ar}), 7.20–7.26 (m, 3H, H_{Ar}), 7.52–7.64 (m, 4H, H_{Ar}), 8.27 (dt, *J* 7.0 and 1.2 Hz, 1H, H_{Ar}).


¹³C NMR (CD₂Cl₂, 75 MHz) δ 113.0, 116.7 (d, *J*_{CF} 22 Hz), 118.6, 123.8, 124.6, 125.2, 126.2 (d, *J*_{CF} 3 Hz), 130.5 (d, *J*_{CF} 8 Hz), 133.1, 146.6, 163.0 (d, *J*_{CF} 247 Hz).

References:


1. Padmanaban, M.; Biju, A. T.; Glorius, F. *Org. Lett.* **2011**, 13, 98–101.
2. Liégault, B.; Lapointe, D.; Caron, L.; Vlassova, A.; Fagnou, K. *J. Org. Chem.* **2009**, 74, 1826–1834.
3. Sun, L.-L.; Deng, C.-L.; Tang, R.-Y.; Zhang, X.-G. *J. Org. Chem.* **2011**, 76, 7546–7550.
4. Bryan, C. S.; Braunger, J. A.; Lautens, M. *Angew. Chem., Int. Ed.* **2009**, 48, 7064–7068.
5. Ohta, A.; Akita, Y.; Ohkuwa, T.; Chiba, M.; Fukunaga, R.; Miyafuji, A.; Nakata, T.; Tani, N.; Aoyagi, Y. *Heterocycles* **1990**, 31, 1951.
6. Lange, P. P.; Gooßen, L. J.; Podmore, P.; Underwood, T.; Sciammetta, N. *Chem. Commun.* **2011**, 47, 3628.
7. Tamba, S.; Okubo, Y.; Tanaka, S.; Monguchi, D.; Mori, A. *J. Org. Chem.* **2010**, 75, 6998–7001.
8. Join, B.; Yamamoto, T.; Itami, K. *Angew. Chem., Int. Ed.* **2009**, 48, 3644–3647.
9. Roger, J.; Požgan, F.; Doucet, H. *Green Chem.* **2009**, 11, 425–432.
10. Wu, Z.; Pan, Y.; Zhou, X. *Synthesis* **2011**, 2011, 2255–2260.
11. Fu, H. Y.; Chen, L.; Doucet, H. *J. Org. Chem.* **2012**, 77, 4473–4478.




02142012-45-anthonyMM
AM-12




02152012-37-anthonyMR
AM-12



02222012-10-anthonyMM
AM-23-1



02252012-37-anthonyMR
AM-23



05252012-4-anthonyMM
AM-44
CD2Cl2

Chemical structure of the complex: Cc1ccc(cc1N2C=CN(C2)c3cc(C)c(C)cc3)c4cc(C)c(C)cc4 (Simplified representation of the complex shown in the image).

¹H NMR spectrum (CD₂Cl₂) showing peaks (ppm) and integration values:

Peak (ppm)	Integration
7.46	5.07
7.44	8.04
7.43	8.07
7.41	12.17
7.38	8.02
7.30	1.94
7.21	1.94
7.19	2.00
7.17	1.02
7.15	1.00
7.09	1.03
7.07	30.63
7.05	0.98
7.03	
6.94	
6.93	
6.92	
6.91	
6.90	
6.73	
6.71	
6.69	
5.86	
5.70	
5.41	
5.32 (Solvent)	
4.96	
4.95	
4.94	
4.93	
4.89	
4.46	
2.55	
2.53	
2.52	
2.50	
2.26	
2.25	
1.17	
1.14	

55262012-25-anthonyMR
AM-44
CD2Cl2

183.14

142.48
142.37
142.04
141.57
141.54
141.40
138.74
138.62
136.34
130.89
130.27
129.50
129.21
128.92
128.02
127.45
123.93


109.38

91.00


54.00 Methylene Chloride-d2
51.17
47.83

22.03
21.29
21.25


04282012-16-anthonyMR
AM-24
CD2Cl2




04282012-14-anthonyMM
AM-24
CD2Cl2




05072012-50-anthonyMM
AM-93
CD2Cl2




05072012-66-anthonyMM
AM-93
CD2Cl2




04282012-15-anthonyMR
AM-78
CD2Cl2




04282012-15-anthonyMM
AM-78
CD2Cl2




04272012-7-anthonyMM
AM-79
CD₂Cl₂




04282012-10-anthonyMM
AM-79
CD₂Cl₂




05022012-15-anthonyMR
AM-89
CD2Cl2




05042012-6-anthonyMR
AM-89
CD2Cl2




05052012-26-anthonyMR
AM-94
CD2Cl2




05052012-28-anthonyMR
AM-94
CD2Cl2




05072012-10-anthonyMR
AM-81
CD2Cl2




05072012-17-anthonyMR
AM-81
CD2Cl2




05022012-16-anthonyMR
AM-90
CD2Cl2




05032012-27-anthonyMR
AM-90
CD2Cl2




05032012-28-anthonyMR
AM-91
CD2Cl2




05032012-28-anthonyMR
AM-91
CD2Cl2




05042012-5-anthonyMR
AM-92
CD2Cl2




05052012-16-anthonyMM
AM-92
CD2Cl2




05102012-14-anthonyMR
AM-100
CD2Cl2




05102012-14-anthonyMR
AM-100
CD2Cl2




05172012-42-anthonyMM
AM-107
CD₂Cl₂




05172012-12-anthonyMR
AM-107
CD₂Cl₂




05182012-32-anthonyMR
AM-108
CD₂Cl₂




05182012-5-anthonyMR
AM-108
CD₂Cl₂




05142012-11-anthonyMR
AM-99
CD2Cl2




05162012-5-anthonyMR
AM-99
CD2Cl2




05162012-10-anthonyMI
AM-104
CD₂Cl₂



05162012-6-anthonyMR
AM-104
CD₂Cl₂



05162012-7-anthonyMR
AM-105
CD2Cl2



05162012-7-anthonyMR
AM-105
CD2Cl2

